Senzime AB (publ), a medical device company, develops and markets patient monitoring systems to monitor patients under anesthesia in Europe, Oceania, Asia, Canada, and the United States. The company offers TetraGraph, a monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; TetraSens electrode array, which has two proximal stimulating electrodes for recording and reference; TetraConnect, a data management portal that helps clinician to access, view, and export data records from the TetraGraph in PDF or Excel format; TetraGraph Device Connectivity, which transfers data from the TetraGraph Monitor to patient monitoring systems; and TetraGraph Philips Interface that enables the transmission of neuromuscular monitoring parameters, TOFC, TOFR, PTC, and TOF bars to Philips patient monitors, as well as TetraGraph readings are displayed on the Philips Intellivue Monitor. It also develops CliniSenz Analyzer for postoperative and continuous patient monitoring in hospital environments; and Onzurf Probe, a sterile CE-marked single use product based on micro-dialysis technology that enables continuous sampling from gastro-intestinal organs, such as esophagus, stomach, and liver. Senzime AB (publ) has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to Root monitoring system, as well as to their digital hubs to interface with the hospital clinical information system/electronic health records. The company was incorporated in 1999 and is based in Uppsala, Sweden.
General Outlook
In simple terms, Senzime AB (publ) has 105.122 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.240% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -4.756%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -3.912%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust -0.315% return, is a testament to Senzime AB (publ)'s adeptness in optimizing resource deployment. Senzime AB (publ)'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.395%. Furthermore, the proficiency of Senzime AB (publ) in capital utilization is underscored by a remarkable -0.407% return on capital employed.
Stock Prices
Senzime AB (publ)'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $6.74, while its low point bottomed out at $6.1. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Senzime AB (publ)'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”